Insilico Medicine Joins HKEX Tech 100 Index, Spotlighting AI-Driven Drug Discovery
Event summary
- Insilico Medicine added to HKEX Tech 100 Index effective September 14, 2026, broadening exposure to AI value chain opportunities.
- Company reported $106M revenue in H1 2026, up 287% YoY, with adjusted net profit exceeding $51M.
- Total contract value of 2026 collaborations reached $7.3B, pushing cumulative deal value since 2021 to $11B.
- Insilico nominated nine drug candidates in nine months, with Rentosertib advancing to Phase III trials for IPF.
The big picture
Insilico's inclusion in the HKEX Tech 100 Index validates its position at the intersection of AI and biotech, where generative AI is transforming drug discovery. The company's rapid revenue growth and expanding partnership network reflect broader industry trends toward AI-driven R&D efficiency. With $11B in cumulative deal value since 2021, Insilico is emerging as a key player in the AI value chain, particularly in the high-growth biotech sector.
What we're watching
- Pipeline Productivity
- Whether Insilico can sustain its record-breaking drug candidate nomination pace.
- Clinical Milestones
- The pace at which Rentosertib and other AI-discovered drugs advance through trials.
- Capital Inflows
- How index inclusion impacts trading liquidity and Mainland Chinese investor participation.
Related topics